Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BeiGene
Pharma
FDA challenges broad use of PD-1 drugs in stomach cancer
The FDA is considering a class-wide action against PD-1 inhibitors in stomach cancer and esophageal cancer based on findings from multiple trials.
Angus Liu
Sep 24, 2024 2:30pm
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Sep 13, 2024 8:53am
BeiGene takes top sponsorship spot as lymphoma campaign ramps up
Sep 5, 2024 8:00am
Sanofi, DualityBio, UCB—Fierce Pharma Asia
Aug 30, 2024 8:05am
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Aug 22, 2024 3:28pm
TROP2 ADCs, Merck-Daiichi, Eisai—Fierce Pharma Asia
Aug 9, 2024 8:25am
